Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis

Annals of the American Thoracic Society

Volumn 11, Issue 3, 2014, Pages 342-350

  Nick, Jerry A ^a,b   Moskowitz, Samuel M ^c   Chmiel, James F ^d   Forssén, Anna V ^a   Kim, Sun Ho ^c   Saavedra, Milene T ^a,b   Saiman, Lisa ^e   Taylor Cousar, Jennifer L ^a,b   Nichols, David P ^a,b  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e NewYork Presbyterian Hospital   (United States)

Author keywords

Azithromycin; Cystic fibrosis; Drug drug interaction; Inhaled antibiotic; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM LYSINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; AZTREONAM;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM ISOLATE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG ANTAGONISM; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPUTUM ANALYSIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG INTERACTION; INHALATIONAL DRUG ADMINISTRATION; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; AZTREONAM; CYSTIC FIBROSIS; DRUG INTERACTIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; TOBRAMYCIN; YOUNG ADULT;

EID: 84898756200     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201310-352OC     Document Type: Article

References (40)

1. Cystic Fibrosis Foundation Patient Registry. 2011 Annual Data Report. Bethesda, MD. 2012 [accessed 1 Aug 2013]. Available from: http://www.cff.org/ UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf
2. Courtney JM, Bradley J, Mccaughan J, O'Connor TM, Shortt C, Bredin CP, Bradbury I, Elborn JS. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007;42:525-532. (Pubitemid 46870384)
3. Lopes AJ, Mafort TT, de Sá Ferreira A, Santos de Castro MC, Cássia de Firmida M, de Andrade Marques E. Is the type of chronic pulmonary infection a determinant of lung function outcomes in adult patients with cystic fibrosis? Monaldi Arch Chest Dis 2012;77:122-128.
4. 1 decline in cystic fibrosis: an instrumental variables analysis. Ann Am Thorac Soc 2013;10:205-212.
5. Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, Larosa M, Knoop C, McElvaney N, Lewis SA, et al.; For the AZLI Active Comparator Study Group. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2012;12:130-140.
6. Ramsey BWPM, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al.; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30. (Pubitemid 29024680)
7. Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, et al.; EPIC; ESCF Investigators. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatr Pulmonol 2013;48:943-953.
8. Ruddy J, Emerson J, Moss R, Genatossio A, McNamara S, Burns JL, Anderson G, Rosenfeld M. Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. J Aerosol Med Pulm Drug Deliv 2013;26:69-75.
9. Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 2007;9:11-20. (Pubitemid 46879110)
10. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756. (Pubitemid 37430625)
11. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-984. (Pubitemid 35284109)
12. Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V, Emmett P, Marshall B, Accurso F, Sagel S, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012;142:1259-1266.
13. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006;174:566-570. (Pubitemid 44330550)
14. Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B, Boucher RC, O'Neal WK. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS ONE 2009;4:e5806.
15. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Antiinflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2006;350:977-982. (Pubitemid 44584188)
16. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-689.
17. Nichols DP, Caceres S, Caverly L, Fratelli C, Kim SH, Malcolm K, Poch KR, Saavedra M, Solomon G, Taylor-Cousar J, et al. Effects of azithromycin in Pseudomonas aeruginosa burn wound infection. J Surg Res 2013;183:767-776.
18. Nick J, Chmiel J, Forssen A, Hamblett N, Moskowitz S, Saiman L, Nichols D. Azithromycin appears to inhibit inhaled tobramycin but not aztreonam when targeting P. aeruginosa in the CF airway [abstract]. Pediatr Pulmonol 2013;48:S36:305.
19. Heydorn A, Nielsen AT, Hentzer M, Sternberg C, Givskov M, Ersbøll BK, Molin S. Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology 2000;146:2395-2407.
20. Macdonald D, Cuthbertson L, Doherty C, Campana S, Ravenni N, Taccetti G, Govan JR. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? J Antimicrob Chemother 2010;65:2373-2375.
21. Morosini MI, García-Castillo M, Loza E, Pérez- Vázquez M, Baquero F, Cantón R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 2005;43:4480-4485. (Pubitemid 41298231)
22. Olsen KM, San Pedro G, Gann LP, Gubbins PO, Halinski DM, Campbell GD Jr. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996;40:2582-2585. (Pubitemid 26367648)
23. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10:54-61.
24. Cystic Fibrosis Foundation Patient Registry. 2005 Annual Data Report. Bethesda, MD. 2006 [accessed 1 Aug 2013]. Available from: http://www.cff.org/ UploadedFiles/research/ClinicalResearch/2005-Patient- Registry.pdf
25. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123:1495-1502. (Pubitemid 36549768)
26. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001;120:118S-123S.
27. Tré-Hardy M, Nagant C, El Manssouri N, Vanderbist F, Traore H, Vaneechoutte M, Dehaye JP. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother 2010;54:4409-4415.
28. Dales L, Ferris W, Vandemheen K, Aaron SD. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 2009;28:1275-1279.
29. Imamura Y, Higashiyama Y, Tomono K, Izumikawa K, Yanagihara K, Ohno H, Miyazaki Y, Hirakata Y, Mizuta Y, Kadota J, et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob Agents Chemother 2005;49:1377-1380. (Pubitemid 40463365)
30. Montenez JP, Van Bambeke F, Piret J, Brasseur R, Tulkens PM, Mingeot-Leclercq MP. Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models. Toxicol Appl Pharmacol 1999;156:129-140. (Pubitemid 29196576)
31. D'amato RF, Thornsberry C, Baker CN, Kirven LA. Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin polymyxin B, and carbenicillin. Antimicrob Agents Chemother 1975;7:596-600.
32. Jackson GG, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990;162:408-413. (Pubitemid 20239956)
33. Khalil H, Chen T, Riffon R, Wang R, Wang Z. Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52:1635-1641. (Pubitemid 351614654)
34. Vaara M. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. Antimicrob Agents Chemother 1993;37:354-356. (Pubitemid 23046584)
35. Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP, Iglewski BH. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2005;49:3858-3867. (Pubitemid 41233042)
36. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-282. (Pubitemid 19071957)
37. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
38. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219. (Pubitemid 36143396)
39. Matthews JN, Altman DG. Interaction 3: how to examine heterogeneity. BMJ 1996;313:862. (Pubitemid 26335214)
40. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC; Macrolide Study Group. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172:1008-1012. (Pubitemid 41476538)